检索结果-南通市图书馆

Journal of Clinical and Nursing Research 2024年第1期8卷 1-6页

作者： Hailing Lin Yanjie Lu Qingdao Shibei District People’s Hospital Qingdao 266011Shandong ProvinceChina

Objective:To analyze the clinical efficacy of tiotropium bromide(TB)combined with budesonide formoterol(BUD/FM)inhalation in treating chronic obstructive pulmonary disease(COPD).Methods:62 COPD patients admitted to the hospital between June 2020 and December 2022 were selected as samples for this *** patients were divided into a combination group and a conventional group using the random number table method,with 31 cases in each *** patients in the combination group were treated with TB combined with BUD/FM inhalation,whereas the patients in the conventional group were treated with BUD/FM inhalation *** treatment efficacy and changes in lung function indicators of both groups were ***:The total efficacy of treatment in the combined group was higher than that in the conventional group,and the difference was statistically significant(P0.05).After three months of treatment,all lung function indicators of the combined group were higher than those of the conventional group,and the difference was statistically significant(P<0.05).Conclusion:Combining TB with BUD/FM inhalation therapy increases the efficacy of treatment for patients with ***,it also improves lung function and leads to a better prognosis.

关键词： tiotropium bromide Budesonide formoterol Inhalation therapy Chronic obstructive pulmonary disease

Evaluation of the efficacy and safety of tiotropium bromide （5 μg） inhaled via Respimat in Chinese patients with chronic obstructive pulmonary disease

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Medical Journal 2013年第19期126卷 3603-3607页

作者： TANG Yah Dan Massey ZHONG Nan-shan State Key Laboratory of Respiratory Disease/Guangzhou Institute ofRespiratory Disease Guangzhou Medical University GuangzhouGuangdong 510120 China Boehringer Ingelheim Limited Bracknell UK

Background A pharmacokinetic study in an Asian population showed that tiotropium 5 μg via Respimat leads to the same plasma levels compared to 18 μg via *** objective of the trial was to compare the efficacy and safety of longterm treatment （1 year） with tiotropium bromide （5 μg） via Respimat（R） with placebo in patients with chronic obstructive pulmonary disease （COPD）.Methods A total of 3991 patients were randomized in this double-blind,placebo controlled,parallel group study,while in China 338 patients （309 males,29 females） received either tiotropium bromide （n=167） or placebo （n=171）.tiotropium bromide solution or matching placebo was delivered via Respimat（R） at a dosage of 5 μg （2 x 2.5 μg/puff） once daily for 48 ***-primary endpoints were trough forced expiratory volume in one second （FEV1） and the time to first *** Statistically significant improvements in trough FEV1 and trough forced vital capacity （FVC） in the tiotropium group were achieved at weeks 4,24,and 48 compared with those in the placebo group.A statistically significant difference （P=0.0027） in favour of tiotropium was also observed for the time to first *** total numbers of exacerbations during treatment were 90 and 128 in the tiotropium and placebo groups,respectively,with a rate ratio of 0.69 （P=0.0164）.The difference between the treatment groups in the adjusted mean changes from baseline of *** Respiratory Questionnaire （SGRQ） total score was-3.9 （95% Cl：-7.5,-0.2） and was of statistical significance （P=0.0367）.The incidences of serious adverse events （SAEs） in the tiotropium and placebo groups were 16.2% and 17.0%,*** deaths occurred whilst patients were on treatment,four in the tiotropium group and three in the placebo group,all of which were assessed as non-related study drugs by the *** tiotropium significantly improved lung function and quality of life,delayed the time to first exacerbation,reduced t

关键词： chronic obstructive pulmonary disease tiotropium bromide anticholinergic pulmonary function

Effect of tiotropium bromide on Expression of CD_8^+CD_(25)^+FoxP_3^+ Regulatory T Cells in Patients with Stable Chronic Obstructive Pulmonary Disease

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Huazhong University of Science and Technology(Medical Sciences) 2011年第4期31卷 463-468页

作者：张建初邓莉熊先智王佩辛建保马万里 Department of Respiratory Diseases Union HospitalTongji Medical CollegeHuazhong University of Science and Technology

The expression of CD8＋CD25＋FoxP3＋ regulatory T cells（CD8＋Tregs） in the peripheral blood of patients with stable chronic obstructive pulmonary disease（COPD）,and the effect of muscarinic cholinergic receptor antagonist tiotropium bromide on the expression of CD8＋Tregs were ***-three patients with moderate to severe stable COPD were enrolled in this *** patients inhaled tiotropium bromide（18 μg daily） for 3 *** and after inhalation of tiotropium bromide,peripheral blood samples were collected from the patients,and T cells were labeled by three-color labeled monoclonal *** cytometry was used to detect the quantity and percentage of CD8＋T cells,CD8＋CD25＋T cells,CD8＋Tregs,CD4＋T cells,CD4＋CD25＋T cells and CD4＋CD25＋FoxP3＋ regulatory T cells（CD4＋Tregs） *** percentage of CD4＋T cells was increased from（27.82±2.18）% to（35.53±1.3）%（t=3.20,P=0.004） in the peripheral blood of patients with stable COPD after inhalation of tiotropium bromide for 3 months,that of CD4＋CD25＋T cells was decreased from（10.03 ±1.42）% to（4.21 ±0.65）%（t=3.78,P=0.001）,and that of CD8＋Tregs was increased from（8.41 ±1.68）% to（21.34 ±4.20）%（t=2.72,P=0.013）.At baseline,CD8＋T cells,CD8＋CD25＋T cells and CD4＋Tregs were detectable in the peripheral blood,but no significant changes were observed after *** correlation analysis revealed that the difference before and after treatment in CD4＋T cells and CD4＋CD25＋T cells was negatively correlated with the ratio of change in CD8＋Tregs before and after treatment（r=-0.61,P=0.013;r=-0.72,P=0.001 respectively）.In the peripheral blood of patients with stable COPD,there was the expression of CD8＋Tregs and CD4＋*** receptor antagonist,tiotropium bromide,can promote the amplification of CD4＋T cells,inhibit the expression of CD25＋T cells,and enhance the expression of CD8＋***8＋Tregs and CD4＋Tregs can be used as new indicators to understand the immune status of *** are helpful in judging

关键词： chronic obstructive pulmonary disease regulatory T cells tiotropium bromide

Effects of Combined Inhalation of Budesonide,Formoterol,and tiotropium bromide on Arterial Blood Gas and Pulmonary Function Indexes in Patients with Chronic Obstructive Pulmonary Disease

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Journal of Clinical and Nursing Research 2023年第5期7卷 49-54页

作者： Changli Chen Ganluo County People's Hospital Liangshan Yi Autonomous Prefecture 616850Sichuan ProvinceChina

Objective:To analyze the effect of combined inhalation of budesonide formoterol and tiotropium bromide on arterial blood gas and pulmonary function indexes in patients with chronic obstructive pulmonary disease(COPD).Methods:100 patients with COPD treated from January to December 2022 were selected as observation objects,and were divided into a control group(n=50,in which budesonide and formoterol were administered)and an experimental group(n=50,the treatment drug was budesonide formoterol combined with tiotropium bromide)according to the computer grouping method,and compared the treatment ***:(i)Before treatment,there was no difference in the partial pressure of carbon dioxide and partial pressure of oxygen between the control group and the experimental group(P>0.05);after treatment,the partial pressure of carbon dioxide and partial pressure of oxygen in the experimental group were higher than those in the control group,with significant differences(P0.05);after treatment,the FVC,FEV1,and FEV1/FVC in the experimental group were significantly higher than those in the control group(P0.05);after treatment,the levels of CRP,IL-6,and TNF-αin the experimental group were lower than those in the control group,with significant differences(Ptiotropium bromide has demonstrated a clear therapeutic efficacy and safety in treating chronic obstructive pulmonary ***

关键词： Budesonide formoterol tiotropium bromide Chronic obstructive pulmonary disease Arterial blood gas Lung function

Feasibility of tiotropium bromide Treatment in Patients with Asthma-COPD Overlap Syndrome and its Effect on Lung Function

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Clinical and Nursing Research 2023年第4期7卷 100-104页

作者： Li Sheng Hohhot First Hospital Hohhot 010030Inner MongoliaChina

Objective:To explore the feasibility of tiotropium bromide therapy and its effect on the lung function of patients with asthma-COPD overlap syndrome(ACOS).Method:The 58 subjects selected in this study were all ACOS patients admitted to our hospital(Hohhot First Hospital)from October 2020 to October *** were grouped according to the random number table method and divided into a control group(29 cases)and an observation group(29 cases).The control group received routine treatment plus salmeterol-fluticasone powder inhalation treatment,and the observation group received tiotropium bromide *** relevant indicators of the two groups were ***:The total clinical effective rate of the observation group was significantly higher than that of the control ***,the forced vital capacity(FVC),forced expiratory volume in 1 second(FEV1)levels,and ACT scores of the two groups increased after treatment,with the observation group having better results than the control *** residual volume-total lung capacity ratio(RV/TLC),acute exacerbation frequency,and CAT scores all decreased,with the observation group showing smaller values than the control *** difference between the results of both groups were significant(Ptiotropium bromide has a significant clinical effect in the treatment of ACOS patients and can effectively improve the lung function of patients.

关键词： Asthma-COPD overlap syndrome tiotropium bromide Lung function Feasibility